Healthcare / BiotechnologyTaipei Exchange
$38.15
-0.35 (-0.91%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 23%
FCF escenarios
weak_data · normalized FCF $-80.3M · quality 67.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
33/100
D
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$2.0B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-19.4%
↓Gross Margin
-98.3%
↓Debt/Equity
0.02
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+30.7%
FCF CAGR
—
FCF margin
-7556.0%
FCF / Net income
0.93x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $1.2M · net income $-97.5M · FCF $-91.0M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $1.2M | $1.2M | $1.7M | $4.8M | $540000.00 |
| Net Income | $-97.5M | $-97.5M | $-104.9M | $-61.0M | $-55.8M |
| EBITDA | $-89.7M | $-89.7M | $-97.9M | $-56.6M | $-54.0M |
| EPS | — | — | -2.43 | -1.60 | -2.11 |
| Gross Margin | -98.3% | -98.3% | 60.2% | 99.1% | 85.9% |
| Operating Margin | -8260.9% | -8260.9% | -6685.3% | -1357.1% | -10636.7% |
| Net Margin | -8089.0% | -8089.0% | -6226.9% | -1257.7% | -10329.4% |
| Balance Sheet | |||||
| Debt/Equity | 0.02 | 0.02 | 0.02 | 0.03 | 0.00 |
| Current Ratio | 24.12 | 24.12 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-91.0M | $-91.0M | $-80.3M | $-74.2M | $-78.4M |
| Returns | |||||
| ROE | -19.4% | -19.4% | -16.6% | -11.4% | -15.5% |
| Valuation | |||||
| P/B | 3.40 | 3.40 | 2.37 | 4.57 | 3.98 |
| Growth & Yield | |||||
| Revenue Growth | -28.5% | -28.5% | -65.3% | 798.1% | — |
| EPS Growth | — | — | -51.8% | 24.4% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+3.1%
Start / end P/E
n/dx → n/dx
EPS bridge
-2.43 → n/d
Residual
+3.1%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.